Together, these data show that allosteric activation of CYP46A1 is a neuron-specific CE- and pTau-lowering treatment with less adverse effects on astrocytes and provides a therapeutic approach to reduce pTau accumulation in early AD-neurons. Here, CYP46A1 is linked to Alzheimer disease.